Crinetics Pharmaceuticals (FRA:6Z4) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Z4 Crinetics Pharmaceuticals Inc FRA:6Z4
50 GF Score
Price €70.90
GF Value €626.58
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:6Z4
50GF Score
Crinetics Pharmaceuticals Inc FRA:6Z4
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of €70.90 is trading 88.7% below its estimated GF Value™ of €626.58. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:6Z4:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €626.58 vs. price of €70.90 (88.7% below fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges CRNX:USA
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
50GF Score

Get the complete analysis for FRA:6Z4

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.90
Price
€626.58
GF Value